EVENTS:   The Roaring 2020s or a Rerun of the 1970s? - Edward Yardeni/Yardeni Research - 24 Mar 26   Best Equity Short Ideas Conference Call 13 - Thomas Chanos/Badger Consultants & Dr. Aaron Fletcher/Bios Research & Jonathan Telgener/Channel Dynamics & Ed Steele/Iron Blue Financials & John Zolidis/Quo Vadis Capital & Mark Hiley/The Analyst - 26 Mar 26     ROADSHOWS: Chinese Equity Ideas & Channel Checks Across 50 sub-sectors - Don Ma /Horizon Insights   •   London   23 - 27 Mar 26       Long Short European Equity Research - Harry Grist /The Analyst   •   New York   26 Mar 26       Fundamental US Healthcare Short Ideas - Dr Elliot Favus /Favus Institutional Research   •   London   27 - 27 Mar 26      
Filters

Fortnightly Publication Highlighting Latest Insights From IRF Providers

Company Research

Atlas Arteria (ALX)

Industrials

Insight Investment Research

Robert Crimes maintains a Sell rating on ALX, citing limited upside vs. broader infrastructure peers and mixed asset quality. While ALX’s stake in APRR delivers robust FCF and steady distribution growth, its minority position and concession expiry in 2035 limit long-term value. The Chicago Skyway deal offers modest value, but DG is deeply value-destructive, with equity estimated 70% below ALX’s 2017 purchase price. ALX's infrastructure distributions are set to rise to A$920m by 2030E but collapse to A$250m in 2037E. Robert expects IFM to increase its stake, but it has had a negative impact on the share price to date and cut daily trading liquidity in half. He continues to prefer Ferrovial (+100% upside) and Getlink (+85%) in Global Toll Roads.

Edition: 212

- 30 May, 2025


Atlas Arteria (ALX)

Industrials

Aequitas Research

Aims to raise ~US$2bn to fund the purchase of its majority interest in Chicago Skyway - ALX’s largest shareholder, IFM (who recently increased their stake to 19.99%) has already publicly stated its opposition for the deal, nonetheless the company has chosen to go ahead with the acquisition. The performance of the shares are likely to be driven more by what IFM does next rather than the company’s fundamentals. The deal scores a negative score on Aequitas’ ECM framework owing to its large size and not being accretive to earnings in the near term - this is one to avoid for new shareholders even at the entitlement offer price.

Edition: 144

- 16 September, 2022